J&J seeks approval for single-dose Covid-19 vaccine in India

It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers

Johnson & Johnson (J&J) has sought approval for its single shot Covid-19 vaccine from the Indian regulator this week.  It is not clear whether, like Pfizer and Moderna, it is seeking indemnity against legal action that may arise from any side-effects.

The company did not comment on the matter but a government official indicated that, unlike Pfizer and Moderna, J&J had an Indian partner which would make the indemnity issue less complicated.

This will be the fourth foreign vaccine to enter India after Russia’s Sputnik V, Pfizer-BioNTech and Moderna. Sputnik V is already approved in India and Hyderabad-based firm Dr Reddy’s Laboratories